938443-23-3

Usage

Uses

Used in Pharmaceutical Industry:
Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, relis used as a potential pharmaceutical agent for its bioactive properties. Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel-'s complex structure and specific stereochemistry may contribute to its interaction with biological targets, offering potential therapeutic applications.
Used in Materials Science:
In the field of materials science, Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, relmay be utilized for the development of novel materials with unique properties. Its heterocyclic structure and functional groups could be exploited to create materials with specific characteristics for various applications.
Further research is necessary to explore the specific biological activities and potential applications of Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, relin these industries.

InChI:InChI=1/C17H22ClN5O2/c1-11-9-23(10-12(2)25-11)17-20-15-13(3-4-14(18)19-15)16(21-17)22-5-7-24-8-6-22/h3-4,11-12H,5-10H2,1-2H3/t11-,12+

Upstream product

• 58584-92-2 2-amino-6-chloronicotinic acid 
• 938443-20-0 2,4,7-trichloropyrido[2,3-d]pyrimidine 
• 938443-19-7 7-chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 45597-00-0 (3R,5S)-3,5-dimethylmorpholine 
• 938443-21-1 4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)morpholine 
• 141-91-3 cis-2,6-dimethylmorpholine 

Downstream Products

• 938443-29-9 7-(3-chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 1424432-35-8 C₂₆H₃₄N₆O₃ 
• 1424432-36-9 C₂₅H₃₂N₆O₂ 
• 1424432-37-0 C₂₆H₃₄N₆O₂ 
• 938440-64-3 KU-63794 

Relevant academic research and scientific papers

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

We describe a novel series of potent inhibitors of the kinase activity of mTOR. The compounds display good selectivity relative to other PI3K-related kinase family members and, in cellular assays, inhibit both mTORC1 and mTORC2 complexes and exhibit good antiproliferative activity.

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer

PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

There is provided compounds of formula (I), which are suitable for the treatment of cancer.